| Visualitzacions | |
|---|---|
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer | 69 |
| gener 2024 | febrer 2024 | març 2024 | abril 2024 | maig 2024 | juny 2024 | juliol 2024 | |
|---|---|---|---|---|---|---|---|
| Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer | 7 | 31 | 1 | 3 | 4 | 12 | 11 |
| Visualitzacions | |
|---|---|
| artconlli_a2018_tabernero_josep_phase II_study_Dual_EGFR.pdf | 17 |
| Visualitzacions | |
|---|---|
| Estats Units | 28 |
| Xina | 4 |
| Bulgària | 3 |
| Espanya | 3 |
| Bèlgica | 2 |
| Corea del Sud | 1 |
| Visualitzacions | |
|---|---|
| Menlo Park | 10 |
| Mountain View | 6 |
| Oakland | 5 |
| San Diego | 5 |
| Barcelona | 3 |
| Jackson | 2 |
| Shanghai | 2 |
| Guangzhou | 1 |
| Xingtai | 1 |